These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34796106)

  • 1. Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.
    Shao D; Du D; Liu H; Lv J; Cheng Y; Zhang H; Lv W; Wang S; Lu L
    Front Oncol; 2021; 11():721318. PubMed ID: 34796106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
    BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
    Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
    Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
    [No Abstract]   [Full Text] [Related]  

  • 5. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV
    Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J
    Front Oncol; 2020; 10():57. PubMed ID: 32133282
    [No Abstract]   [Full Text] [Related]  

  • 6. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.
    Yang L; Xu P; Li M; Wang M; Peng M; Zhang Y; Wu T; Chu W; Wang K; Meng H; Zhang L
    Front Oncol; 2022; 12():894323. PubMed ID: 35800046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.
    Wang TW; Chao HS; Chiu HY; Lu CF; Liao CY; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
    Transl Oncol; 2024 Jan; 39():101826. PubMed ID: 37984256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.
    Zhang X; Lu B; Yang X; Lan D; Lin S; Zhou Z; Li K; Deng D; Peng P; Zeng Z; Long L
    Eur Radiol; 2023 Feb; 33(2):825-835. PubMed ID: 36166088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
    Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
    EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of interim
    Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
    Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
    Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
    PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
    Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
    Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of
    Yang B; Ji H; Zhong J; Ma L; Zhong J; Dong H; Zhou C; Duan S; Zhu C; Tian J; Zhang L; Wang F; Zhu H; Lu G
    Front Oncol; 2020; 10():567160. PubMed ID: 33262942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Radiomics Nomogram Based on
    Yang B; Zhong J; Zhong J; Ma L; Li A; Ji H; Zhou C; Duan S; Wang Q; Zhu C; Tian J; Zhang L; Wang F; Zhu H; Lu G
    Front Oncol; 2020; 10():1042. PubMed ID: 32766134
    [No Abstract]   [Full Text] [Related]  

  • 15. A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy.
    He L; Li Z; Chen X; Huang Y; Yan L; Liang C; Liu Z
    Chin J Cancer Res; 2021 Oct; 33(5):592-605. PubMed ID: 34815633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
    Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
    BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of pre-therapy
    Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
    Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
    Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomics Analysis of PET and CT Components of
    Wang X; Lu Z
    Front Oncol; 2021; 11():638124. PubMed ID: 33928029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.